Skip to main content
. 2019 Mar 26;24(9):1270–1284. doi: 10.1634/theoncologist.2018-0112

Table 3. Ongoing or planned phase III clinical trials of immune checkpoint blockers in metastatic NSCLC.

image

Abbreviations: ALK, anaplastic lymphoma kinase gene; EGFR, epidermal growth factor receptor; NCT, National Clinical Trial; NSCLC, non‐small cell lung cancer; OS, overall survival; pCX, platinum‐based chemotherapy; PD‐1, programmed cell death‐1 receptor; PD‐L1, programmed cell death ligand‐1; PFS, progression‐free survival; SoC, standard of care.